MedTrace Logo

Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)

NCT02593188 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 264

Last updated 2022-10-18

No results posted yet for this study

Summary

The purpose of the proposed study is to acquire additional data (including the assessment of anti-rHuPH20 antibodies) on the long-term safety of HYQVIA and to assess the prescribed treatment regimens and treatment administration in routine clinical practice.

Conditions

  • Primary Immunodeficiency Diseases (PID)

Interventions

BIOLOGICAL

HYQVIA

Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase

Sponsors & Collaborators

  • Baxalta now part of Shire

    lead INDUSTRY

Principal Investigators

  • Shire Director · Shire

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-12
Primary Completion
2021-10-21
Completion
2021-10-21

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02593188 on ClinicalTrials.gov